Documenti analoghi

• Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( EAP )
  di: Akimichi Morita, et al.
  Pubblicazione: (2025)
• Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics
  di: Koji Kamiya, et al.
  Pubblicazione: (2025)
• Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial
  di: Shinichi Imafuku, et al.
  Pubblicazione: (2024)
• Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial
  di: Yukari Okubo, et al.
  Pubblicazione: (2025)
• Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics
  di: Koji Kamiya, et al.
  Pubblicazione: (2025)